BioNTech Shares Fall 5.3% as $1 Billion Buyback Fails to Offset 1,860 Job Cuts and Growing Losses

BioNTech’s stock suffered its steepest single-day slide in months on Monday, dropping 5.3 percent, as investors weighed two divergent signals from the Mainz-based biotech. The company has simultaneously authorised a $1 billion share repurchase programme and unveiled plans to eliminate roughly 1,860 jobs, closing plants in Germany and Singapore. The move highlights a strategic pivot that is pleasing no one in the short term: shareholders see buybacks, but also deepening losses from the COVID-to-oncology transition.

The buyback, covering American Depositary Shares and valid until May 2027, draws on BioNTech’s hefty war chest. At the end of March, the company held €16.8 billion in cash and marketable securities. Yet the first-quarter numbers tell a stark story: revenue collapsed to €118.1 million from €182.8 million a year earlier, and the net loss ballooned to €531.9 million. Research and development spending alone reached €557 million, underscoring the cost of chasing cancer therapies after the pandemic windfall faded.

Management is attacking the cost base with equal force. Around 450 positions are being cut at the Marburg facility alone, part of a wider reduction that also hits sites in Idar-Oberstein and Singapore. The company projects annual savings of about €500 million by 2029, with separate reports citing a target of nearly $585 million. Analyst Harry Gillis of Berenberg trimmed his price target to $140 from $155 but kept a buy rating, pointing to three catalysts: the $1 billion buyback, falling fixed costs from plant closures, and progress on 15 oncology programmes now in late-stage development.

Should investors sell immediately? Or is it worth buying BioNTech?

Brussels is providing helpful cover. The European Parliament and Council have agreed on new rules to bolster domestic drug manufacturing. Public procurement will increasingly weigh supply security over price, and lawmakers are considering a quota requiring half of active ingredients for essential medicines to come from the EU. Strategic projects such as vaccines will receive accelerated approvals and dedicated funding, shielding BioNTech from low-cost Asian competitors that currently dominate the European market.

The company’s future hinges on its oncology pipeline. BioNTech reaffirmed its 2026 revenue guidance of €2.0–2.3 billion and expects seven late-stage data readouts this year from its immunomodulator and antibody-drug conjugate programmes. Two candidates stand out: pumitamig, which has entered five new pivotal trials in triple-negative breast and non-small cell lung cancers, and gotistobart, whose Phase 3 PRESERVE-003 study demonstrated a more than 50% reduction in mortality risk in certain lung cancer patients. The goal is to bring the first cancer immunotherapy to market by the end of the year.

Despite the pipeline narrative, the share price remains under pressure. The stock trades at around €79, roughly 4% lower than at the start of 2026 and below its 50-day moving average. All 13 analysts covering the stock rate it a buy, but the market is waiting for those late-stage data to materialise before assigning a higher valuation. For now, the combination of a $1 billion buyback, massive job cuts, and a €532 million quarterly loss leaves investors in a holding pattern — one that only the oncology results can break.

Ad

BioNTech Stock: New Analysis - 12 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH | boerse | 69315693 |